Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 5
2004 1
2005 3
2006 7
2007 7
2008 7
2009 7
2010 14
2011 13
2012 8
2013 3
2014 2
2015 6
2016 6
2017 3
2018 5
2019 8
2020 5
2021 8
2022 7
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

121 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean Jonathan C. trend (1 results)?
Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma.
Tap WD, Villalobos VM, Cote GM, Burris H, Janku F, Mir O, Beeram M, Wagner AJ, Jiang L, Wu B, Choe S, Yen K, Gliser C, Fan B, Agresta S, Pandya SS, Trent JC. Tap WD, et al. Among authors: trent jc. J Clin Oncol. 2020 May 20;38(15):1693-1701. doi: 10.1200/JCO.19.02492. Epub 2020 Mar 24. J Clin Oncol. 2020. PMID: 32208957 Free PMC article. Clinical Trial.
Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial.
Wilky BA, Trucco MM, Subhawong TK, Florou V, Park W, Kwon D, Wieder ED, Kolonias D, Rosenberg AE, Kerr DA, Sfakianaki E, Foley M, Merchan JR, Komanduri KV, Trent JC. Wilky BA, et al. Among authors: trent jc. Lancet Oncol. 2019 Jun;20(6):837-848. doi: 10.1016/S1470-2045(19)30153-6. Epub 2019 May 8. Lancet Oncol. 2019. PMID: 31078463 Clinical Trial.
Radiation Therapy for Treatment of Soft Tissue Sarcoma in Adults: Executive Summary of an ASTRO Clinical Practice Guideline.
Salerno KE, Alektiar KM, Baldini EH, Bedi M, Bishop AJ, Bradfield L, Chung P, DeLaney TF, Folpe A, Kane JM, Li XA, Petersen I, Powell J, Stolten M, Thorpe S, Trent JC, Voermans M, Guadagnolo BA. Salerno KE, et al. Among authors: trent jc. Pract Radiat Oncol. 2021 Sep-Oct;11(5):339-351. doi: 10.1016/j.prro.2021.04.005. Epub 2021 Jul 26. Pract Radiat Oncol. 2021. PMID: 34326023
Immunotherapy Strategies for Gastrointestinal Stromal Tumor.
Arshad J, Costa PA, Barreto-Coelho P, Valdes BN, Trent JC. Arshad J, et al. Among authors: trent jc. Cancers (Basel). 2021 Jul 14;13(14):3525. doi: 10.3390/cancers13143525. Cancers (Basel). 2021. PMID: 34298737 Free PMC article. Review.
What Clinical Trials Are Needed for Treatment of Leiomyosarcoma?
Kasper B, D'Ambrosio L, Davis EJ, Ingham M, Broto JM, Trent JC, van Houdt WJ, Van Tine BA. Kasper B, et al. Among authors: trent jc. Curr Treat Options Oncol. 2022 Mar;23(3):439-449. doi: 10.1007/s11864-021-00928-y. Epub 2022 Mar 11. Curr Treat Options Oncol. 2022. PMID: 35275323 Free PMC article. Review.
Latest advances in adult gastrointestinal stromal tumors.
Florou V, Wilky BA, Trent JC. Florou V, et al. Among authors: trent jc. Future Oncol. 2017 Oct;13(24):2183-2193. doi: 10.2217/fon-2017-0245. Epub 2017 Oct 6. Future Oncol. 2017. PMID: 28984483 Review.
Rethinking placebos: embracing synthetic control arms in clinical trials for rare tumors.
Serrano C, Rothschild S, Villacampa G, Heinrich MC, George S, Blay JY, Sicklick JK, Schwartz GK, Rastogi S, Jones RL, Rutkowski P, Somaiah N, Navarro V, Evans D, Trent JC. Serrano C, et al. Among authors: trent jc. Nat Med. 2023 Nov;29(11):2689-2692. doi: 10.1038/s41591-023-02578-z. Nat Med. 2023. PMID: 37828359 No abstract available.
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments.
Stacchiotti S, Maria Frezza A, Demetri GD, Blay JY, Bajpai J, Baldi GG, Baldini EH, Benjamin RS, Bonvalot S, Bovée JVMG, Callegaro D, Casali PG, D'Angelo SP, Davis EJ, Dei Tos AP, Demicco EG, Desai J, Dileo P, Eriksson M, Gelderblom H, George S, Gladdy RA, Gounder MM, Gupta AA, Haas R, Hayes A, Hohenberger P, Jones KB, Jones RL, Kasper B, Kawai A, Kirsch DG, Kleinerman ES, Le Cesne A, Maestro R, Martin Broto J, Maki RG, Miah AB, Palmerini E, Patel SR, Raut CP, Razak ARA, Reed DR, Rutkowski P, Sanfilippo RG, Sbaraglia M, Schaefer IM, Strauss DC, Strauss SJ, Tap WD, Thomas DM, Trama A, Trent JC, van der Graaf WTA, van Houdt WJ, von Mehren M, Wilky BA, Fletcher CDM, Gronchi A, Miceli R, Wagner AJ. Stacchiotti S, et al. Among authors: trent jc. Cancer Treat Rev. 2022 Nov;110:102455. doi: 10.1016/j.ctrv.2022.102455. Epub 2022 Aug 18. Cancer Treat Rev. 2022. PMID: 36031697 Review.
121 results